CIK 0001157601 · Large accelerated filer
MADRIGAL PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- MDGL
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- (267) 824-2827
- Business address
- 1001 CONSHOHOCKEN STATE ROAD, SUITE 2-350, WEST CONSHOHOCKEN, PA
- Former names
- MADRIGAL PHARMACEUTICALS, INC., SYNTA PHARMACEUTICALS CORP
- Open-market buys, last 90 days
- $35,023,032
- in 1 filing
- Open-market sales, last 90 days
- $7,011,938
- in 3 filings, $6.7M under 10b5-1 plans
Net +$28,011,094. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-04-08 | FRIEDMAN PAUL A Director | Option exercise 10b5-1 | +26,270 | $9.45 | $248K | 212,005 |
| 2024-04-08 | FRIEDMAN PAUL A Director | Sale 10b5-1 | −1,441 | $242.95 | $350K | 210,564 |
| 2024-04-08 | FRIEDMAN PAUL A Director | Sale 10b5-1 | −3,730 | $244.12 | $911K | 206,834 |
| 2024-04-08 | FRIEDMAN PAUL A Director | Sale 10b5-1 | −5,663 | $244.86 | $1.4M | 201,171 |
| 2024-04-08 | FRIEDMAN PAUL A Director | Sale 10b5-1 | −2,078 | $245.71 | $511K | 199,093 |
| 2024-04-08 | FRIEDMAN PAUL A Director | Sale 10b5-1 | −5,028 | $246.96 | $1.2M | 194,065 |
| 2024-04-08 | FRIEDMAN PAUL A Director | Sale 10b5-1 | −3,464 | $247.76 | $858K | 190,601 |
| 2024-04-08 | FRIEDMAN PAUL A Director | Sale 10b5-1 | −4,866 | $248.59 | $1.2M | 185,735 |
| 2024-04-08 | FRIEDMAN PAUL A Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −26,270 | 206,256 | ||
| 2024-04-05 | Taub Rebecca Pres., R&D, and CMO | Option exercise 10b5-1 | +27,506 | $9.45 | $260K | 486,505 |
| 2024-04-05 | Taub Rebecca Pres., R&D, and CMO | Sale 10b5-1 | −1,643 | $240.11 | $394K | 484,862 |
| 2024-04-05 | Taub Rebecca Pres., R&D, and CMO | Sale 10b5-1 | −700 | $241.14 | $169K | 484,162 |
| 2024-04-05 | Taub Rebecca Pres., R&D, and CMO | Sale 10b5-1 | −8,817 | $242.61 | $2.1M | 475,345 |
| 2024-04-05 | Taub Rebecca Pres., R&D, and CMO | Sale 10b5-1 | −8,989 | $243.33 | $2.2M | 466,356 |
| 2024-04-05 | Taub Rebecca Pres., R&D, and CMO | Sale 10b5-1 | −2,079 | $244.45 | $508K | 464,277 |
| 2024-04-05 | Taub Rebecca Pres., R&D, and CMO | Sale 10b5-1 | −5,278 | $245.53 | $1.3M | 458,999 |
| 2024-04-05 | Taub Rebecca Pres., R&D, and CMO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −27,506 | 79,240 | ||
| 2024-04-05 | FRIEDMAN PAUL A Director | Option exercise 10b5-1 | +27,613 | $9.45 | $261K | 213,348 |
| 2024-04-05 | FRIEDMAN PAUL A Director | Sale 10b5-1 | −1,420 | $240.10 | $341K | 211,928 |
| 2024-04-05 | FRIEDMAN PAUL A Director | Sale 10b5-1 | −612 | $241.15 | $148K | 211,316 |
Page 31 of 82 · 1,629 trades